This suggests that alterations of the SL metabolism might be an important component of PD neuropathology, not only in carriers of GBA1 mutations but also for sporadic PD patients where age-associated reduction in GCase activity might contribute to the onset of the pathology. The gene discussed is GBA1; the disease is Parkinson disease.